Financial Support for Patients Taking TIBSOVO®
ServierONE works to connect you to the right support programs and services that help with the cost of TIBSOVO.
We offer:
- Support with insurance coverage and reimbursement
- Financial assistance to help you pay for TIBSOVO
- Tools and resources to help navigate the world of insurance
- Access to a one-on-one Patient Experience Manager
Explore Important Details for All TIBSOVO Financial Support Programs
The Copay Program Limits Copay Amounts for Patients with Commercial Insurance
The Copay Program lowers the out-of-pocket cost of TIBSOVO for eligible patients with commercial prescription insurance to no more than $25 per prescription if your copay exceeds that amount.
- U.S./Puerto Rico resident
- Available to eligible patients with commercial/private prescription insurance paying a portion of their cost
- Patients participating in government prescription insurance are not eligible
- Apply for the Copay Program at ServierONE-copay.com
Enroll in the Copay Program
Get StartedKey Features
Financial Assistance: The ServierONE Copay Program offers financial support to eligible patients to help cover copayments, coinsurance, or deductible costs associated with treatment.
Easy Enrollment: You can easily enroll in the Copay Program by completing a simple application process.
Supportive Services: In addition to copay assistance, the program may also provide access to support services, such as reimbursement navigation and financial counseling, to help alleviate the financial burden of treatment.
Renewable Benefits: Eligible patients may take advantage of the ServierONE Copay Program for multiple prescription refills, ensuring continued access to treatment without the added financial strain.
If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.
The TIBSOVO® QuickStart Program Can Help During a Delay in Insurance Coverage
The QuickStart Program is intended for patients who experience an insurance coverage delay lasting five or more business days. If eligible, you will receive one, 30-day supply as prescribed by your healthcare provider. If there is a further delay in coverage, you may be eligible to receive another 30-day supply refill per Servier approval.
- U.S./Puerto Rico resident
- Commercially or government insured
- Have completed the TIBSOVO enrollment form
Apply to the QuickStart Program via Fax
Work with your healthcare provider to apply by completing the appropriate sections of the TIBSOVO Enrollment Form and then your healthcare provider will fax to Servier Patient Support Program at 1-844-409-1143
Key Features
Covers insurance delays: Eligible new patients facing coverage delays of 5 or more business days may receive a prescription with an option for a refill, totaling 60 days, upon submission of a completed prior authorization.
Seamless process: QuickStart prescriptions will be reviewed and filled by ServierONE. If using a network specialty pharmacy, they will collaborate with ServierONE to ensure uninterrupted access to treatments.
If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.
The Patient Assistance Program (PAP) Helps Uninsured and Underinsured Patients Access Important Treatments
PAP is dedicated to assisting uninsured and underinsured patients by offering medication to those who meet our eligibility criteria. This program is designed to ensure that financial constraints do not hinder access to a prescribed Servier treatment. The benefits of PAP are reassessed at the beginning of each calendar year.
- U.S./Puerto Rico resident
- Commercially, privately, or government insured
- Have completed the TIBSOVO Enrollment Form
- Financial Qualification: Household gross annual income does not exceed 600% of the US Federal Poverty Level
Fill out the appropriate sections of the TIBSOVO Enrollment Form and then work with your healthcare provider to complete it. Your healthcare provider will fax your completed form to ServierONE Patient Support Program at 1-844-409-1143.
Download TIBSOVO Enrollment FormSupport Through Independent Foundations Is Also Available
Other forms of assistance may be available, including assistance from independent foundations for patients with government and commercial insurance. Network specialty pharmacies or Servier can provide a referral to one of these foundations. Eligibility is determined by the individual foundation. Servier is not affiliated with these organizations but can assist you in navigating eligibility.
Unsure if you qualify for the program? Please call 1-800-813-5905 to talk with a Patient Experience Manager today.
How to enroll in the Patient Assistance Program (PAP)
1
2
3
4
5
If you do not meet the eligibility criteria, ServierONE Patient Support Program may be able to identify alternate sources of coverage.
If You Have Questions or Need Assistance, Contact ServierONE Patient Support Program.
Key Features
Overview: The Servier Patient Assistance Program provides uninsured and underinsured patients access to their treatment as needed by offering medication to those who meet our eligibility criteria.
Enrollment: Our dedicated program representatives are available to support patients with the application process, including guidance on required = 'true' documentation and eligibility requirements.
If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.
How TIBSOVO® Prescriptions Are Filled for You
Because TIBSOVO is a specialty medication, it’s not available through your local drugstore. Once your doctor sends in your prescription, you can get TIBSOVO through a specialty pharmacy (a mail-order pharmacy that provides specialty drugs), from your doctor’s office, or from your hospital pharmacy.
Throughout the process, you may be contacted by your specialty pharmacy or Servier over the phone. Please keep in mind that this call may come from a number you may not recognize.
If you have questions, please call 1-800-813-5905 , Monday through Friday, 8 AM to 8 PM ET.
TIBSOVO® IMPORTANT SAFETY INFORMATION AND APPROVED USES
TIBSOVO may cause serious side effects, including
- Differentiation Syndrome. Differentiation syndrome is a common condition, which can be serious, that affects your blood cells and may be life-threatening or lead to death. Differentiation syndrome in adults with AML and MDS has happened as early as 1 day and up to 3 months after starting TIBSOVO.
-
Call your healthcare provider or go to the nearest
hospital emergency room right away if you develop any of
the following symptoms of differentiation syndrome during
treatment with TIBSOVO:
- fever
- cough
- trouble breathing
- rash
- decreased urination
- dizziness or lightheadedness
- rapid weight gain
- swelling of your arms and legs
If you develop signs and symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine or a medicine called hydroxyurea and may monitor you in the hospital.
- Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before and during treatment with TIBSOVO. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint
-
Guillain-Barré Syndrome has happened in
people treated with TIBSOVO. Your healthcare provider will
monitor you for nervous system problems and will
permanently stop your treatment with TIBSOVO if you
develop Guillain-Barré syndrome. Tell your healthcare
provider right away if you develop any signs or symptoms
of Guillain-Barré syndrome, including:
- weakness or tingling feeling in your legs, arms, or upper body
- numbness and pain on one side or both sides of your body
- any changes in your ability to see, touch, hear, or taste
- burning or prickling sensation
- difficulty breathing
The most common side effects of TIBSOVO when used in combination with azacitidine or alone in adults with AML include:
- changes in certain blood cell counts
- diarrhea
- increased blood sugar
- fatigue
- changes in certain liver function tests
- swelling of arms or legs
- decreased levels of electrolytes in the blood
- nausea
- vomiting
- decreased appetite
- joint pain
- shortness of breath
- uric acid increased
- stomach (abdominal) pain
- changes in certain kidney function tests
- pain or sores in your mouth or throat
- rash
- irregular heart rhythm or heartbeat (QTc prolongation)
- differentiation syndrome
- muscle pain
The most common side effects of TIBSOVO when in adults with MDS include:
- changes in certain kidney function tests
- changes in certain blood cell counts
- joint pain, back pain, or neck pain
- decreased levels of albumin in the blood
- changes in certain liver function tests
- fatigue
- diarrhea
- cough
- decreased levels of sodium in the blood
- pain or sores in your mouth or throat
- decreased appetite
- muscle pain
- decreased levels of phosphorus in the blood
- itchy skin
- rash
The most common side effects of TIBSOVO in adults with Cholangiocarcinoma include:
- fatigue
- nausea
- abdominal pain
- diarrhea
- cough
- decreased appetite
- fluid and swelling in your stomach area
- vomiting
- hemoglobin decreased (anemia)
- rash
- change in liver function tests
Your healthcare provider will do blood tests before you start and during treatment with TIBSOVO. Your healthcare provider may decrease, temporarily hold, or permanently stop your treatment with TIBSOVO if you develop certain side effects. TIBSOVO may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all of the possible side effects of TIBSOVO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Before taking TIBSOVO, tell your healthcare provider about all of your medical conditions, including if you:
- have any heart problems, including a condition called long QT syndrome
- have problems with abnormal electrolytes, such as sodium, potassium, calcium, or magnesium levels
- have nervous system problems
- have problems with your kidneys or are on dialysis
- have any liver disorders, including cirrhosis
- are pregnant or plan to become pregnant. TIBSOVO can cause harm to your unborn baby. You should avoid becoming pregnant during treatment with TIBSOVO. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with TIBSOVO
- are breastfeeding or plan to breastfeed. It is not known if TIBSOVO passes into your breast milk. Do not breastfeed during your treatment with TIBSOVO and for 1 month after your last dose of TIBSOVO
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take hormonal contraceptives. TIBSOVO may affect how hormonal contraceptives work and may cause them to not work as well.
Please see Full Prescribing Information including BOXED WARNING for AML and MDS patients and Medication Guide.
What is TIBSOVO?
TIBSOVO is a prescription medicine used to treat adults with
an isocitrate dehydrogenase-1 (IDH1) mutation with:
-
acute myeloid leukemia (AML):
- with newly diagnosed AML treated in combination with azacitidine or alone who are 75 years or older or who have health problems that prevent the use of certain chemotherapy treatments
- when the disease has come back or has not improved after previous treatment(s)
-
myelodysplastic syndrome (MDS):
- when the disease has come back or has not improved after previous treatment(s)
-
bile duct cancer (cholangiocarcinoma):
- with bile duct cancer that has spread and
- who have already received previous treatment(s)
Your healthcare provider will perform a test to make sure that TIBSOVO is right for you. It is not known if TIBSOVO is safe and effective in children.
TIBSOVO may cause serious side effects, including
- Differentiation Syndrome. Differentiation syndrome is a common condition, which can be serious, that affects your blood cells and may be life-threatening or lead to death. Differentiation syndrome in adults with AML and MDS has happened as early as 1 day and up to 3 months after starting TIBSOVO.
-
Call your healthcare provider or go to the nearest
hospital emergency room right away if you develop
any of the following symptoms of differentiation
syndrome during treatment with TIBSOVO:
- fever
- cough
- trouble breathing
- rash
- decreased urination
- dizziness or lightheadedness
- rapid weight gain
- swelling of your arms and legs
If you develop signs and symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine or a medicine called hydroxyurea and may monitor you in the hospital.
- Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before and during treatment with TIBSOVO. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint
-
Guillain-Barré Syndrome has
happened in people treated with TIBSOVO. Your
healthcare provider will monitor you for nervous
system problems and will permanently stop your
treatment with TIBSOVO if you develop Guillain-Barré
syndrome. Tell your healthcare provider right away
if you develop any signs or symptoms of
Guillain-Barré syndrome, including:
- weakness or tingling feeling in your legs, arms, or upper body
- numbness and pain on one side or both sides of your body
- any changes in your ability to see, touch, hear, or taste
- burning or prickling sensation
- difficulty breathing
The most common side effects of TIBSOVO when used in combination with azacitidine or alone in adults with AML include:
- changes in certain blood cell counts
- diarrhea
- increased blood sugar
- fatigue
- changes in certain liver function tests
- swelling of arms or legs
- decreased levels of electrolytes in the blood
- nausea
- vomiting
- decreased appetite
- joint pain
- shortness of breath
- uric acid increased
- stomach (abdominal) pain
- changes in certain kidney function tests
- pain or sores in your mouth or throat
- rash
- irregular heart rhythm or heartbeat (QTc prolongation)
- differentiation syndrome
- muscle pain
The most common side effects of TIBSOVO when in adults with MDS include:
- changes in certain kidney function tests
- changes in certain blood cell counts
- joint pain, back pain, or neck pain
- decreased levels of albumin in the blood
- changes in certain liver function tests
- fatigue
- diarrhea
- cough
- decreased levels of sodium in the blood
- pain or sores in your mouth or throat
- decreased appetite
- muscle pain
- decreased levels of phosphorus in the blood
- itchy skin
- rash
The most common side effects of TIBSOVO in adults with Cholangiocarcinoma include:
- fatigue
- nausea
- abdominal pain
- diarrhea
- cough
- decreased appetite
- fluid and swelling in your stomach area
- vomiting
- hemoglobin decreased (anemia)
- rash
- change in liver function tests
Your healthcare provider will do blood tests before you start and during treatment with TIBSOVO. Your healthcare provider may decrease, temporarily hold, or permanently stop your treatment with TIBSOVO if you develop certain side effects. TIBSOVO may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all of the possible side effects of TIBSOVO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Before taking TIBSOVO, tell your healthcare provider about all of your medical conditions, including if you:
- have any heart problems, including a condition called long QT syndrome
- have problems with abnormal electrolytes, such as sodium, potassium, calcium, or magnesium levels
- have nervous system problems
- have problems with your kidneys or are on dialysis
- have any liver disorders, including cirrhosis
- are pregnant or plan to become pregnant. TIBSOVO can cause harm to your unborn baby. You should avoid becoming pregnant during treatment with TIBSOVO. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with TIBSOVO
- are breastfeeding or plan to breastfeed. It is not known if TIBSOVO passes into your breast milk. Do not breastfeed during your treatment with TIBSOVO and for 1 month after your last dose of TIBSOVO
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take hormonal contraceptives. TIBSOVO may affect how hormonal contraceptives work and may cause them to not work as well.
Please see Full Prescribing Information including BOXED WARNING for AML and MDS patients and Medication Guide.
What is TIBSOVO?
TIBSOVO is a prescription medicine used to treat
adults with an isocitrate dehydrogenase-1 (IDH1)
mutation with:
-
acute myeloid leukemia (AML):
- with newly diagnosed AML treated in combination with azacitidine or alone who are 75 years or older or who have health problems that prevent the use of certain chemotherapy treatments
- when the disease has come back or has not improved after previous treatment(s)
-
myelodysplastic syndrome (MDS):
- when the disease has come back or has not improved after previous treatment(s)
-
bile duct cancer (cholangiocarcinoma):
- with bile duct cancer that has spread and
- who have already received previous treatment(s)
Your healthcare provider will perform a test to make sure that TIBSOVO is right for you. It is not known if TIBSOVO is safe and effective in children.
Support Bot
Online
-
Welcome to the ServierONE chatbot!
I’m here to help you find information and resources on the ServierONE website.
Before we get started, are you a patient or a healthcare provider?